Company: BNBX
Filing Date: 2025-01-10
Form Type: S-1/A
Source: 0001104659-25-002521
Chunk: 7

Company: BNB PLUS CORP.
Filing Date: 2025-01-10
Form: S-1/A
Chunk 7
---
 molecular diagnostics and genetic testing services (“MDx Testing Services”); and (iii) the
manufacture and detection of DNA for industrial supply chains and security services (“DNA Tagging and Security Products and Services”).

Our current growth strategy is to primarily
focus our resources on the further development, commercialization, and customer adoption of our Therapeutic DNA Production Services,
including the expansion of our contract development and manufacturing operation (“CDMO”) for the manufacture of synthetic
DNA and associated enzymes for use in the production of nucleic acid-based therapies.

We will continue to update our business strategy
and monitor the use of our resources regarding our various business segments. The Company’s management is currently engaged in
a strategic review of the Company’s business segments that may result in the closure or divestiture of the Company’s DNA
Tagging and Security Products and Services and/or MDx Testing Services, as well as workforce reductions and potential management changes.
To this end, on December 17, 2024, the Company announced it is exploring the potential closure or divestiture of its DNA Tagging and
Security Products and Services business segment. No assurance can be given that a closure or divestiture will be completed. Further,
the definitive terms and structure of any possible closure or divestiture have not been determined or approved by the Company’s
board of directors (the “Board of Directors”). Although the purpose of any closure or divestiture would be to reduce the
Company’s expenses and effectuate cost savings, it is possible that there may be related restructuring costs. We expect that based
on available opportunities and our beliefs regarding future opportunities, we will continue to modify and refine our business strategy.

Therapeutic DNA Production Services

Through our LineaRX (“LRx”), Inc.
subsidiary we are developing and commercializing our LineaDNA and Linea IVT platforms for the manufacture of synthetic DNA and associated
enzymes for use in the production of nucleic acid-based therapeutics.

LineaDNA Platform

Our LineaDNA platform is our core enabling
technology, and enables the rapid, efficient, and large-scale cell-free manufacture of high-fidelity DNA sequences for use in the manufacturing
of a broad range of nucleic acid-based therapeutics. The LineaDNA platform enzymatically produces a linear form of DNA we call “LineaDNA”
that is an alternative to plasmid-based DNA manufacturing technologies that have supplied the DNA used in biotherapeutics for the past
40 years.

As of the third quarter